EURORDIS’ priorities for the revision of the Orphan Medicinal Products Regulation
For the first time since its adoption in 2000, the European Commission is in the process of modernising the Orphan Medicinal Products Regulation. In anticipation of the proposed revision, EURORDIS has identified four key areas for improvement based on a leaked draft text.
OpenEdition vous propose de citer ce billet de la manière suivante :
bartosb (5 octobre 2023). EURORDIS’ priorities for the revision of the Orphan Medicinal Products Regulation. ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/o6eu





